HTB

Conference reports

29th Conference on Retroviruses and Opportunistic Infections (CROI 2022): final report

CROI 2022: NAMSAL study comparing DTG to EFV400 in Cameroon: week 192 results

29th Conference on Retroviruses and Opportunistic Infections (CROI 2022): further reports

CROI 2022: Updates from the VESTED study

CROI 2022: Switching to dolutegravir for adults on stable PI-based second-line ART

29th Conference on Retroviruses and Opportunistic Infections (CROI 2022): third reports

CROI 2022: Dolutegravir plus recycled tenofovir rather than switch to AZT: public health approach to second-line ART

CROI 2022: Other COVID-19 studies

29th Conference on Retroviruses and Opportunistic Infections (CROI 2022): second reports

CROI 2022: Webcasts now online and open access

CROI 2022: Islatravir studies for HIV treatment and PrEP

CROI 2022: UK study reports diabetes mellitus in 9% of HIV positive Africans in the UK on stable ART

CROI 2022: Life expectancy reduced by eight years following hospitalisation for a mental health condition in South Africa

CROI 2022: Long COVID persists for over a year: evidence for divergent immune responses

CROI 2022: Risk factors for NAFLD and proteinuria in HIV positive people on ART

CROI 2022: UK study shows PEP is started earlier using home starter packs

CROI 2022: Summary of 14 key studies on HIV and liver disease

CROI 2022: Genomic entrapment of HIV in people on long-term ART, chimeric antigen receptor T cells and more on bNAbs

29th Conference on Retroviruses on Opportunistic Infections (CROI 2022): First reports

CROI 2022: Biktarvy (B/F/TAF): 5-year follow-up in two phase 3 studies

CROI 2022: Injectable CAB/RPV-LA results after three years follow-up

CROI 2022: Lenacapavir: 54 week results in treatment-naive participants of CALIBRATE study

CROI 2022: Lenacapavir in treatment-experienced participants, and as PrEP in macaques

CROI 2022: Fourth potential stem cell HIV cure – in a US woman using donor cord cells

CROI 2022: Strategies to suppress viral load off-ART with 3BNC117, 10-1074 and other bNAbs

CROI 2022: Targetting reservoir with ART + bNAb 3BNC117 + romidepsin maintained undetectable viral load off-ART for 3.7 years in one case

CROI 2022: Dual bNAb treatment maintains undetectable viral load off-ART in 44% of children in the Tatelo Study

CROI 2022: AAV8-VRC07 vaccine generates new bNAb production in HIV positive people for up to three years

CROI 2022: No impact from high-dose vitamin D3 on reducing the HIV viral reservoir

CROI 2022: Higher maternal mortality and adverse birth outcomes among women with COVID-19 in Botswana

CROI 2022: ANCHOR study reduces anal cancer by 57% and supports screening for people living with HIV

CROI 2022: Other studies on anal cancer

CROI 2022: Telomere shortening associated with TAF but not TDF in CHARTER study

CROI 2022: Injectable PrEP: impressive results, new viral load monitoring – but price questions access

CROI 2022: Long-acting doravirine implants as PrEP to prevent vaginal HIV transmission in mouse study

CROI 2022: LEAP Workshop online: research into long-acting drugs

CROI 2022 to only be virtual: programme online

18th International European AIDS Conference (EACS 2021)

EACS case study: how to diagnose HIV on PrEP – stopping PrEP or intensify to ART?

European AIDS Clinical Society honours Simon Collins for longstanding contribution to the field of HIV

18th International European AIDS Conference (EACS 2021)

Lenacapavir: drug resistance after viral rebound in treatment experienced participants

Implications of historical M184V on use of dual dolutegravir/lamivudine ART

Stopping long-acting cabotegravir/rilpivirine: 1 in 5 trial participants didn’t restart oral ART within eight weeks

Islatravir plus doravirine dual ART: 144 week follow-up from phase 2 study

HIV-specific mental health services across the EU

18th International European AIDS Conference (EACS 2021)

EACS 2021: a call for collaborations and for both HIV and COVID-19 

Reduced responses to COVID-19 vaccines at low CD4 counts

EACS Guidelines: 11th edition (October 2021)

Community “Respect my HIV” march: 30 October 2021 in London

11th IAS Conference on HIV Science (IAS 2021)

IAS 2021 website now open access

Substudies from the ODYSSEY trial: results July 2021

Trial design for next generation PrEP

11th IAS Conference on HIV Science (IAS 2021)

IAS 2021: lenacapavir studies show impressive results in naive, extensive drug resistance and potential as PrEP

IAS 2021: HIV pipeline drugs: CAB/RPV LA, fostemsavir, paediatric dolutegravir, lenacapavir, islatravir, MK-8507 and albuvirtide

IAS 2021: Proving efficacy of next generation PrEP: counterfactual controls in lenacapavir and islatravir studies

IAS 2021: WHO report links HIV to 30% increased mortality from COVID-19: based on South African data

IAS 2021: New demands for better transgender heath care: No data no more

13th International Workshop on HIV Paediatrics 2021

Dolutegravir superior to standard-of-care in young children: results from the ODYSSEY trial

5th Joint BHIVA/BASHH Conference 2021

Few vertical HIV transmissions in the UK but contributing factors remain associated with inequality

Post navigation